Look­ing for first-in-class glo­ry, Boehringer In­gel­heim ac­quires two pre­clin­i­cal can­cer drugs from Ver­sant-backed biotech

Wad­ing deep­er in­to the next wave of im­muno-on­col­o­gy, Boehringer In­gel­heim has bought up a Ver­sant-launched pre­clin­i­cal pipeline fo­cused on the tu­mor mi­croen­vi­ron­ment.

The ac­qui­si­tion of North­ern Bi­o­log­ics — a sub­sidiary of the Toron­to-based biotech North­ern LP — po­si­tions Boehringer at the fore­front of the stro­mal bi­ol­o­gy space, the com­pa­ny said. North­ern Bi­o­log­ics will con­tin­ue plow­ing on the pre­clin­i­cal front un­til the Ger­man phar­ma takes over the clin­i­cal, reg­u­la­to­ry and com­mer­cial work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER